News articles about WuXi PharmaTech (Cayman) (NYSE:WX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. WuXi PharmaTech (Cayman) earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.8515312052646 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2017/08/18/wuxi-pharmatech-cayman-nysewx-receives-coverage-optimism-score-of-0-16-updated-updated.html.
WuXi PharmaTech (Cayman) Company Profile
WuXi PharmaTech (Cayman) Inc is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers.
Receive News & Ratings for WuXi PharmaTech (Cayman) Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
